Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with Type2 diabetes: An open-label randomized trial

Diabetic Medicine

Volumn 30, Issue 1, 2013, Pages 109-113

  Nauck, M ^a   Horton, E ^b   Andjelkovic, M ^c   Ampudia Blasco, F J ^d   Parusel, C T ^c   Boldrin, M ^e   Balena, R ^c,f  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b JOSLIN DIABETES CENTER   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOFFMANN LA ROCHE INC   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA; TASPOGLUTIDE;

ADULT; AGED; APPETITE DISORDER; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE NODULE; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871093044     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12003     Document Type: Article

References (13)

1. Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J et al.Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010; 151: 2474-2482.
2. Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type2 diabetes. Diabet Med 2009; 26: 1156-1164.
3. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009; 32: 1237-1243.
4. Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med 2010; 27: 556-562.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al.Medical management of hyperglycemia in type2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
6. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl 1): 1-68.
7. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G et al.Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
8. Workgroup on Hypoglycemia; American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
9. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K et al.Once weekly exenatide compared with insulin glargine titrated to target in patients with type2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
10. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
11. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
12. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al.Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
13. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J et al.Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.